Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
Not Applicable
Recruiting
- Conditions
- Tumor Pancreas
- Interventions
- Drug: BGT007H Cell Injection
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06478225
- Locations
- 🇨🇳
Renji hospital, Shanghai, Shanghai, China
Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06476301
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
Not yet recruiting
- Conditions
- Circulating Tumor CellLeukapheresisProstate Cancer
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06469710
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University, Shanghai, China
Effectiveness and Health Economics of Endoluminal Treatment of Arteriovenous Graft Fistula.
Recruiting
- Conditions
- Hemodialysis Access Failure
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT06470646
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06458010
- Locations
- 🇨🇳
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Effectiveness and Health Economics of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure
Recruiting
- Conditions
- Hemodialysis Access Failure
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 480
- Registration Number
- NCT06454396
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
A Clinical Prospective Observational Study of Near Infrared Spectroscopy to Detect Subcranial Hematoma
Recruiting
- Conditions
- Intracranial Hemorrhages
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06404645
- Locations
- 🇨🇳
Brain Injury Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Label-free Raman Spectroscopy for Discrimination Between Breast Cancer Tumor and Adjacent Tissues After Neoadjuvant Treatment
Not yet recruiting
- Conditions
- Diagnosis
- Interventions
- Diagnostic Test: Diagnostic Test
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06394050
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
Not Applicable
Recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: PlaceboBiological: Telitacicept
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 176
- Registration Number
- NCT06394063
- Locations
- 🇨🇳
Ren Ji Hospital, Shanghai, China
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
Phase 1
Recruiting
- Conditions
- ImmunotherapyLocally Advanced Cervical CarcinomaConcurrent Chemoradiotherapy
- Interventions
- Drug: Albumin-Bound Paclitaxel, cisplatin, Sintilimab
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06391190
- Locations
- 🇨🇳
RenJi hospital, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath